These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32387436)

  • 1. Pharmacokinetics/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a proof-of-concept study.
    Lin YW; Chang RY; Rao GG; Jermain B; Han ML; Zhao JX; Chen K; Wang JP; Barr JJ; Schooley RT; Kutter E; Chan HK; Li J
    Clin Microbiol Infect; 2020 Sep; 26(9):1229-1235. PubMed ID: 32387436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice.
    Chow MYT; Chang RYK; Li M; Wang Y; Lin Y; Morales S; McLachlan AJ; Kutter E; Li J; Chan HK
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of a Novel Virulent Klebsiella Phage Kp_Pokalde_002 in a Mouse Model.
    Dhungana G; Nepal R; Regmi M; Malla R
    Front Cell Infect Microbiol; 2021; 11():684704. PubMed ID: 34485172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phage Therapy Is Effective in a Mouse Model of Bacterial Equine Keratitis.
    Furusawa T; Iwano H; Hiyashimizu Y; Matsubara K; Higuchi H; Nagahata H; Niwa H; Katayama Y; Kinoshita Y; Hagiwara K; Iwasaki T; Tanji Y; Yokota H; Tamura Y
    Appl Environ Microbiol; 2016 Sep; 82(17):5332-9. PubMed ID: 27342558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the impact of repeated intravenous phage doses on mammalian host-phage interactions.
    Tan X; Chen K; Jiang Z; Liu Z; Wang S; Ying Y; Zhang J; Yuan S; Huang Z; Gao R; Zhao M; Weng A; Yang Y; Luo H; Zhang D; Ma Y
    J Virol; 2024 Jan; 98(1):e0135923. PubMed ID: 38084959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.
    Chang RYK; Chen K; Wang J; Wallin M; Britton W; Morales S; Kutter E; Li J; Chan HK
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation.
    Nang SC; Lin YW; Petrovic Fabijan A; Chang RYK; Rao GG; Iredell J; Chan HK; Li J
    Clin Microbiol Infect; 2023 Jun; 29(6):702-709. PubMed ID: 36736661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mechanism-based pathway toward administering highly active N-phage cocktails.
    Smith NM; Nguyen TD; Chin WH; Sanborn JT; de Souza H; Ho BM; Luong T; Roach DR
    Front Microbiol; 2023; 14():1292618. PubMed ID: 38045026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa.
    Wang J; Hu B; Xu M; Yan Q; Liu S; Zhu X; Sun Z; Reed E; Ding L; Gong J; Li QQ; Hu J
    Int J Mol Med; 2006 Feb; 17(2):309-17. PubMed ID: 16391831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of Pseudomonas aeruginosa veterinary isolates to Pbunavirus PB1-like phages.
    Fujiki J; Furusawa T; Munby M; Kawaguchi C; Matsuda Y; Shiokura Y; Nakamura K; Nakamura T; Sasaki M; Usui M; Iwasaki T; Gondaira S; Higuchi H; Sawa H; Tamura Y; Iwano H
    Microbiol Immunol; 2020 Nov; 64(11):778-782. PubMed ID: 32918505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Susceptibilities of multidrug-resistant pathogens responsible for complicated skin and soft tissue infections to standard bacteriophage cocktails].
    Gündoğdu A; Kılıç H; Ulu Kılıç A; Kutateladze M
    Mikrobiyol Bul; 2016 Apr; 50(2):215-23. PubMed ID: 27175494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.
    Jault P; Leclerc T; Jennes S; Pirnay JP; Que YA; Resch G; Rousseau AF; Ravat F; Carsin H; Le Floch R; Schaal JV; Soler C; Fevre C; Arnaud I; Bretaudeau L; Gabard J
    Lancet Infect Dis; 2019 Jan; 19(1):35-45. PubMed ID: 30292481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single dose of a virulent bacteriophage vB PaeP-SaPL, rescues bacteremic mice infected with multi drug resistant Pseudomonas aeruginosa.
    Alvi IA; Asif M; Ur Rehman S
    Virus Res; 2021 Jan; 292():198250. PubMed ID: 33259872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice.
    Vinodkumar CS; Kalsurmath S; Neelagund YF
    Indian J Pathol Microbiol; 2008; 51(3):360-6. PubMed ID: 18723958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model.
    Manohar P; Nachimuthu R; Lopes BS
    BMC Microbiol; 2018 Aug; 18(1):97. PubMed ID: 30170558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen.
    Roach DR; Leung CY; Henry M; Morello E; Singh D; Di Santo JP; Weitz JS; Debarbieux L
    Cell Host Microbe; 2017 Jul; 22(1):38-47.e4. PubMed ID: 28704651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.
    Malik DJ; Sokolov IJ; Vinner GK; Mancuso F; Cinquerrui S; Vladisavljevic GT; Clokie MRJ; Garton NJ; Stapley AGF; Kirpichnikova A
    Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages.
    Torres-Barceló C; Arias-Sánchez FI; Vasse M; Ramsayer J; Kaltz O; Hochberg ME
    PLoS One; 2014; 9(9):e106628. PubMed ID: 25259735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms.
    Coulter LB; McLean RJ; Rohde RE; Aron GM
    Viruses; 2014 Oct; 6(10):3778-86. PubMed ID: 25285538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells.
    Alemayehu D; Casey PG; McAuliffe O; Guinane CM; Martin JG; Shanahan F; Coffey A; Ross RP; Hill C
    mBio; 2012; 3(2):e00029-12. PubMed ID: 22396480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.